Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06898242

Early Myofascial Manual Treatment in Subjects With Spasticity Following Acquired Brain Injury

Spasticity is characterized by an increase in muscle tone that is velocity-dependent and caused by the exaggeration of the stretch reflex. Clinically, it is found in 70-85% of patients with spinal cord injury at one year, 40-45% in patients with stroke at 12 months, and 25% in patients with traumatic brain injury at one year.

The term 'Severe Acquired Brain Injury' refers to a condition characterized by brain damage that causes a coma with an acute phase score of 8 on the Glasgow Coma Scale (GCS), lasting more than 24 hours. It may be caused by vascular, traumatic, anoxic, infectious, toxic-metabolic, or neoplastic damage, which can cause multiple and complex sensory, cognitive, and behavioral impairments that lead to significant disability. Spasticity occurs frequently in patients with GCA, often at an early stage, with serious repercussions on the rehabilitation process and outcome.

Numerous studies indicate that spasticity due to neurological damage is supported, in addition to hyperexcitable stretch reflexes, by changes in the connective tissues of the peripheral limbs that increase muscle resistance to passive movement. After neurological damage, and starting 1 week after immobilization, alterations in the muscles and connective tissue can be observed: changes in the muscle fibers, changes in the collagen tissue, and changes in the properties of the tendons. It is believed that the quantitative and qualitative changes in the intramuscular connective tissue contribute to the deterioration of the properties and functions of the immobilized muscle, which contributes to the establishment and progression of spasticity.

In patients with spastic paresis, therapeutic interventions are intended to prevent prolonged shortening of the muscles and mobilize the affected areas. According to recent research, the connective tissue is particularly sensitive to mechanical stress, particularly deep manual manipulation and vibration. Several studies have suggested that myofascial release therapy can be a complementary treatment in patients with neurological disorders to reduce muscle spasticity and increase joint mobility.

Myofascial release techniques can be hypothesized to be a valid integrated treatment for spasticity in patients with sequelae from GCA, but their use in this area has been little studied and no studies have been conducted in the post-acute period of intensive hospitalization.

The purpose of the present study is to determine whether manual myofascial release techniques, applied to the upper and lower limbs, are safe, tolerable, and effective in modifying the degree of spasticity and improving functional activity in patients with GCA. Additionally, changes in muscle structure will be evaluated by ultrasound: cross-sectional area, anteroposterior diameter, and pennation angle.

Finally, we will measure the effects of manual myofascial treatment stimulation by measuring electrodermal activity (EDA), which is a non-invasive method in which an electrode bracelet is applied to the patient's right wrist to measure the electrical conductance of the skin, which is a function of the autonomic nervous system, which is controlled by the sweat glands. Various sensory stimulations, including visual, auditory, olfactory, tactile, vestibular, and proprioceptive stimulations, can produce a physical sensation that can influence the patient's sensorimotor output, resulting in physiological changes in the activity of the ANS as a consequence of the processing of sensory afferents. A response to an appropriate sensory stimulus can be regarded as a manifestation of a change in consciousness.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aquired brain injuries from 40 days to 6 months after the event
  • Spasticity at upper orvlower limbs quantified at MAS scale >= than 1
  • Age >= 18 years
  • Patient/Caregiver ability to understand and sign the informed consent

Exclusion criteria

  • Spasticity at MAS scale > 2
  • Non consolidatetd fracture and/or muscle injuries to the limbs
  • Deep vein thrombosis
  • Neoplasms
  • Hemodynamic instability
  • Local infections to the limbs
  • Recent treatment with botulinum toxin (within 40 days)

Treatment and study plan

Manual myofascial treatment direct to upper and lower limb

Other

Manual treatment direct specifically on fascia connective tissue

Rehabilitative treatment following rehabilitation project

Other

Intensive multidisciplinary rehabilitation program for at least 180 minutes/day, 6 days a week, following rehabilitation project

Primary outcomes

  1. Modification of spasticity through Modified Ashworth Scale

    Time frame: Changes from baseline (T0), 4 weeks of treatment (T1), 4 weeks of follow up (T2)

    Evaluation of changes in the degree of spasticity of upper and lower limbs through Modified Ashworth Scale (lower degree 0: no increase in muscle tone; maximum degree 4: affected part rigid in flexion or extension)

Secondary outcomes

  1. Tolerance and safety of treatment

    Time frame: Changes from baseline (T0), 4 weeks of treatment (T1), 4 weeks of follow up (T2)

    Evaluation of safety and tolerability of treatment throught Pain Assessment in Advanced Dementia scale (minimum degree 0: no pain; maximum degree 10: maximum pain)

  2. Evaluation of changes in the degree of functional use of the upper and lower limbs through Motricity Index Scale

    Time frame: Changes from baseline (T0), 4 weeks of treatment (T1), 4 weeks of follow up (T2)

    Motricity Index Scale: minimum degree 0: no movement; maximum degree: movement performed with normal force

Other outcomes

  1. Changes in muscle echostructure

    Time frame: Changes from baseline (T0), 4 weeks of treatment (T1), 4 weeks of follow up (T2)

    Evaluation in muscle echostructure through assessment of cross sectional area (Unit of Measure: cm^2) at medial gemellus muscle and biceps brachii muscle.

  2. Changes in muscle echostructure

    Time frame: Changes from baseline (T0), 4 weeks of treatment (T1), 4 weeks of follow up (T2)

    Evaluation of muscle echostructure through assessment of anterior-posterior diameter (unit of measure: mm) at medial gemellus muscle and biceps brachii muscle.

  3. Changes in muscle echostructure

    Time frame: Changes from baseline (T0), 4 weeks of treatment (T1), 4 weeks of follow up (T2)

    Evaluation of muscle echostructure through assessment of Heckmatt Index at medial gemellus muscle and biceps brachii muscle (unit of measure: prime numbers from 1 to 4; 1: normal aspect of muscle echostructure, clear bone echo; 4: high echointensity of muscle, absent bone echo)

  4. Changes in muscle echostructure

    Time frame: Changes from baseline (T0), 4 weeks of treatment (T1), 4 weeks of follow up (T2)

    Evaluation of muscle echostructure through assessment of pennation angle at medial gemellus muscle and biceps brachii muscle (unit of measure: degrees)

  5. Evaluation of electrodermal activity

    Time frame: Changes from baseline (T0), 4 weeks of treatment (T1), 4 weeks of follow-up (T2)

    Evaluation of modification of skin conductance through assessment of modification of electrodermal activity (unit of measure: prime numbers)

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Acronym: MyosABI

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Mar 27, 2025
Registry last updated
Apr 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.